General
Novonesis expands Asia footprint with $50 million Thailand facility acquisition
Novonesis aims to reinforce its global multipurpose production network while improving proximity to fast-growing customer bases
-
By ICN Bureau | April 19, 2026
Global biosolutions major Novonesis has struck an agreement with Meihua to acquire a production facility in Rayong, Thailand for around USD 50 million. This marks a strategic push to deepen its presence in Southeast Asia and strengthen global supply capabilities.
The move is a key step in the company’s GROW strategy toward 2030, as it doubles down on emerging markets that already account for one-third of its sales and are expected to outpace growth in developed regions.
By investing in strategically located facilities, Novonesis aims to reinforce its global multipurpose production network while improving proximity to fast-growing customer bases.
The acquired site features advanced fermentation capabilities and is designed for further expansion, including potential production of HMO (human milk oligosaccharides).
Novonesis plans additional investments over the coming years to scale up operations, with the facility expected to become commercially operational in 2027.
Anders Lund, Chief Operating Officer, said: “Strengthening our production footprint in Southeast Asia is an important step for Novonesis. A key part of our GROW strategy is to continue to strengthen our resilient and responsive supply network to support our long-term growth ambitions.
"By expanding our world-class production capabilities, we can move closer to customers in a fast-growing region and deliver even greater value to them."
The Thailand acquisition adds to a broader wave of capacity expansion across Novonesis’ global network.
Looking ahead, Novonesis expects to increase growth-focused capital expenditure through the current strategy period toward 2030, positioning itself to meet rising global demand for biosolutions.
